focus -WSS

focus

author：leisure time 2025-09-06 03:17:29 - browse：62

Feng Zhang Editas — Aera was formed to pursue a nanoparticle described by Feng Zhang in 2021. Susan Walsh/AP

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT.

The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds. Aera attributed the layoffs to those headwinds and indicated it had axed a portion of the company dedicated to developing new gene-editing enzymes.

“In 2023, Aera launched to pursue an ambitious mission to develop transformative genetic medicines by harnessing enabling delivery technologies and precision payloads,” spokesman Dan Budwick said in a statement. “Although Aera remains in a strong cash position today, given the current biotech funding environment, we have chosen to take steps to focus our strategy and investments on the development of our novel delivery platforms, thereby further extending our cash runway.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Gritstone Bio's cancer vaccine test, and more on Novartis' deal

WSS

Biogen walks away from Aduhelm, years after polarizing approval

340B reform proposal comes out of Senate working group

Medicare Advantage plans can’t deny care with AI, CMS warns

Why Novartis is going to walk from its acquisition of MorphoSys

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Unique patient identifier: Experts argue the benefits, pitfalls

Wikipedia

focus

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage plans can’t deny care with AI, CMS warns

Alkermes shareholders re

Humana’s losses in Medicare Advantage tank its stock

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Virginia high school admissions case could be legal follow

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

The high cost of giving birth even with insurance

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

focus

AstraZeneca stays mum on Medicare drug pricing negotiations

Investment in vaccine development is lagging, report finds

Why Novartis is going to walk from its acquisition of MorphoSys

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

10 reasons why health care startups fail

Adopting new red light myopia treatments may be short

Wikipedia

hotspot

focus

entertainment